CN105477642B - A kind of florfenicol composition of high bioavilability and preparation method thereof - Google Patents
A kind of florfenicol composition of high bioavilability and preparation method thereof Download PDFInfo
- Publication number
- CN105477642B CN105477642B CN201510934722.9A CN201510934722A CN105477642B CN 105477642 B CN105477642 B CN 105477642B CN 201510934722 A CN201510934722 A CN 201510934722A CN 105477642 B CN105477642 B CN 105477642B
- Authority
- CN
- China
- Prior art keywords
- florfenicol
- composition
- parts
- preparation
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of florfenicol compositions of high bioavilability, it is made of the raw material of following parts by weight: 1~5 part of Florfenicol；2~50 parts of beta-cyclodextrin；5~10 parts of sorbefacient.The florfenicol composition for the high bioavilability that the present invention is screened by many experiments, on the basis of Florfenicol cyclodextrin inclusion compound, add sorbefacient, both the shortcomings that can overcoming Florfenicol that should not be dissolved in water, it is greatly improved its oral administration biaavailability again simultaneously, in addition preparation method provided by the invention, technological design are reasonable, strong operability is, it can be achieved that industrialized production.
Description
Technical field
The present invention relates to field of pharmaceutical preparations, and in particular to a kind of florfenicol composition and its system of high bioavilability
Preparation Method.
Background technique
Florfenicol also known as Fluprofen, Florfenicol, Chinese name: bis- chloro- N- { fluorine first of [R-- (R1.T)] -2,2-
Base) -2- hydroxyl -2- [4- (sulfonyloxy methyl) phenyl] ethyl } acetamide is that 1970s are developed by Schering Plough company, the U.S.
A kind of novel dedicated chloromycetin broad-spectrum antibiotic of beasts of exploitation.Its antimicrobial spectrum is extensive, may act on various bacteria and branch is former
Body, Chlamydia etc..But Florfenicol is practically insoluble in water, and oral administration biaavailability is very low.In order to increase the dissolution of Florfenicol
Property, research focuses mostly in PEG solid dispersions, PVP solid dispersions and Benexate Hydrochloride is made in Florfenicol at present
Deng.The application of these new technologies, improves bioavilability compared with drug suspension to a certain extent.Notification number is CN
The Chinese patent literature of 102885777B, entitled " florfenicol powder composition and preparation method thereof " disclose Florfenicol
Dust composition and preparation method thereof.Florfenicol is dissolved in organic solvent by it, by Florfenicol absorption carrier and absorption enhancement
Agent is dissolved in water, and spray drying is made after the two mixing.Its sorbefacient is disodium ethylene diamine tetraacetate and lauryl sodium sulfate.It is small
After mouse gastric infusion, the maximum blood concentration of florfenicol powder is 1.7 times of bulk pharmaceutical chemicals.Notification number is CN102160854 A, title
A kind of Chinese patent literature for " Florfenicol quick-releasing type water-soluble powder preparation and preparation method thereof for including cyclodextrin " is public
A kind of Florfenicol quick-releasing type water-soluble powder preparation and preparation method thereof for including cyclodextrin of cloth, which only reports fluorine
The dissolution rate that benzene Buddhist nun examines inclusion compound has compared with Florfenicol original powder and by Florfenicol powder preparation prepared by solid dispersion technology
Dissolution rate height and the good feature of dissolubility.Notification number is CN104055727 A, a kind of entitled " florfenicol solid dispersoid
And preparation method thereof " Chinese patent disclose a kind of florfenicol solid dispersoid and preparation method thereof, in PEG and pool Lip river
The solubility that solid acid improves Florfenicol is added on the basis of husky nurse.
Summary of the invention
Goal of the invention: it is poor that the purpose of the present invention is to solve florfenicol water solubles, and oral administration biaavailability is low to ask
Topic, provides a kind of florfenicol composition of high bioavilability, and the composition can not only improve the dissolubility of Florfenicol,
And its oral administration biaavailability can be greatly improved；Another object of the present invention is to provide a kind of fluorobenzene of high bioavilability
Buddhist nun examines the preparation method of composition.
Technical solution: in order to achieve the goal above, the technical scheme adopted by the invention is as follows:
A kind of florfenicol composition of high bioavilability, bulk pharmaceutical chemicals are Florfenicol, auxiliary material include: beta-cyclodextrin and
Sorbefacient, specifically it is to be prepared from the following raw materials in parts by weight: 1~5 part of Florfenicol；2~50 parts of beta-cyclodextrin and
5~10 parts of absorption enhancers.
Preferably, above-described sorbefacient is selected from sodium carboxymethylcellulose, methylcellulose, hydroxypropyl
Cellulose, CARBOPOL 971,30 POVIDONE K 30 BP/USP 15, PVP K30,30 POVIDONE K 30 BP/USP 90, Arabic gum, tragacanth, sodium alginate, shell
Glycan or agar.
The preparation method of the florfenicol composition of high bioavilability provided by the invention, comprising the following steps:
(1) Florfenicol, beta-cyclodextrin and sorbefacient are added in suitable quantity of water by above-mentioned weight part ratio, heating
To 70~90 DEG C, 30~40min is stirred；
(2) solution after above-mentioned stirring is prepared into powder by way of being spray-dried or being lyophilized to get high biology benefit
The florfenicol composition of expenditure.
As another preferred solution, the preparation method of the florfenicol composition of high bioavilability provided by the invention,
The following steps are included:
(1) Florfenicol and beta-cyclodextrin are added in suitable quantity of water by above-mentioned weight part ratio, are heated to 70~90 DEG C,
Stir 30~40min；
(2) solution after above-mentioned stirring is prepared into powder and sorbefacient by way of being spray-dried or being lyophilized
It is uniformly mixed the florfenicol composition to get high bioavilability.
The present invention uses cyclodextrin inclusion technique to include Florfenicol first, effectively improves the dissolution of Florfenicol
Degree, solubility experiment the result shows that, the solubility of Florfenicol raw material medicine is dissolved after forming inclusion compound less than 300ppm at room temperature
Degree reaches 4000ppm.
In order to further increase the oral administration biaavailability of Florfenicol, the present invention is more various by lot of experiments
Promote absorption mechanism, result of study discovery increases solution viscosity, and the bioavilability of Florfenicol inclusion compound can obtain after gastric infusion
To significantly improving.
The present invention gives rat oral gavage Florfenicol to include respectively according to the dosage of 40mg/kg (in terms of Florfenicol) in research
Suspension, the fluorine of the suspension of 0.5% sodium carboxymethylcellulose of object, 0.5% sodium carboxymethylcellulose of Florfenicol raw material medicine
Benzene Buddhist nun examines the aqueous solution of inclusion compound, the results showed that, C of the Florfenicol in blood plasma after administrationmaxRespectively 28.19 μ g/ml,
5.27 μ g/ml and 14.64 μ g/ml (carrying out absorbing the introduction for promoting vapor as representative using sodium carboxymethylcellulose).Fluorine is measured respectively
Benzene Buddhist nun examines 0.5% sodium carboxymethyl cellulose suspension liquid of inclusion compound and the viscosity of aqueous solution, the results showed that, the viscosity of water is 0, and
The viscosity of 0.5% carboxymethylcellulose sodium solution is 86 Pa Secs, after stomach-filling, 0.5% carboxymethyl cellulose of Florfenicol inclusion compound
C of the suspension of plain sodium than the suspension of 0.5% sodium carboxymethylcellulose of Florfenicol raw material medicinemaxImprove 5.35 times, and
C of the suspension of 0.5% sodium carboxymethylcellulose of Florfenicol inclusion compound than the aqueous solution of Florfenicol inclusion compoundmaxIt improves
1.93 times, this result explanation, Florfenicol, which is wrapped in cyclodextrin inner, can effectively improve the oral administration biaavailability of drug；Increase
The viscosity of solubilization liquid is conducive to improve drug in the residence time of gastrointestinal tract, to further increase the bioavilability of drug.
Further to verify, to 1% sodium carboxymethyl cellulose suspension liquid (1% carboxymethyl cellulose of rat oral gavage Florfenicol inclusion compound
The viscosity of plain sodium solution is 187 Pa Secs), CmaxFor 47.14 μ g/ml, compared with 0.5% carboxymethyl of stomach-filling Florfenicol inclusion compound
The C of the suspension of sodium cellulosatemaxImprove 1.67 times.Thus it proves, improves solution viscosity, extend drug in the stagnant of gastrointestinal tract
The time is stayed, the oral administration biaavailability of drug can be improved.
The utility model has the advantages that compared with prior art, the fluorine for the high bioavilability that the present invention is screened by many experiments
Benzene Buddhist nun examines composition, on the basis of Florfenicol cyclodextrin inclusion compound, contains sorbefacient simultaneously, can both overcome fluorobenzene Buddhist nun
The shortcomings that should not being dissolved in water is examined, while being greatly improved its oral administration biaavailability again, many deficiencies of the prior art can be overcome.
In addition preparation method provided by the invention, technological design is reasonable, and strong operability is, it can be achieved that industrialized production.
Detailed description of the invention
Fig. 1 is Florfenicol plasma concentration curve figure after each experimental group administration of the present invention.
Specific embodiment
The present invention is described in detail combined with specific embodiments below.Following embodiment will be helpful to the technology of this field
Personnel further understand the present invention, but the invention is not limited in any way.
Embodiment 1
A kind of florfenicol composition of high bioavilability, it is made of the raw material of following parts by weight:
The preparation method comprises the following steps:
(1) it by 1 part of Florfenicol, 10 parts of beta-cyclodextrin and 5 parts of sodium carboxymethylcellulose, is added in 1 part of water, is heated to 70
~90 DEG C, magnetic agitation 30min；
(2) solution of above-mentioned preparation is prepared into powder by spray dried form to get the fluorobenzene of high bioavilability
Buddhist nun examines composition.
A kind of florfenicol composition of the high bioavilability of embodiment 2, it is by the raw material system of following parts by weight
At:
The preparation method comprises the following steps:
(1) it by 1 part and 15 parts of beta-cyclodextrin of Florfenicol, is added in 3 parts of water, is heated to 70~90 DEG C, magnetic agitation
30min；；
(2) solution of above-mentioned preparation is prepared into powder by spray dried form, is added 903 parts of 30 POVIDONE K 30 BP/USP, mixing is equal
The even florfenicol composition to get high bioavilability.
Embodiment 3
Preparation method:
(1) it by 1 part and 25 parts of beta-cyclodextrin of Florfenicol, is added in 2 parts of water, is heated to 70~90 DEG C, magnetic agitation
30min；；
(2) solution of above-mentioned preparation is prepared by way of freeze-drying powder, is added 10 parts of CARBOPOL 971, mixing is equal
The even florfenicol composition to get high bioavilability.
Embodiment 4
A kind of florfenicol composition of high bioavilability, it is made of the raw material of following parts by weight:
(1) it by 1 part and 45 parts of beta-cyclodextrin of Florfenicol, is added in 5 parts of water, is heated to 70~90 DEG C, magnetic agitation
30min；；
(2) solution of above-mentioned preparation is prepared by way of spray drying powder, is added 8 parts of chitosan, mixing is equal
The even florfenicol composition to get high bioavilability.
Embodiment 5: florfenicol composition provided by the invention is in the intracorporal pharmacokinetic studies of rat:
Experimental method
Rat (male, weight 180-220g) is taken to be randomly divided into 6 groups, every group 10.Overnight fasting before being administered, freely drinks
Water.By taking the florfenicol composition of above-described embodiment 1, embodiment 2, embodiment 3 and embodiment 4 preparation as an example.Stomach-filling is given respectively
Give the Florfenicol that Florfenicol raw material medicine, embodiment 1, embodiment 2, embodiment 3 and the embodiment 4 of same dose are prepared
Composition (Monodispersed is in carboxymethylcellulose sodium solution) and the Florfenicol inclusion compound aqueous solution (40mg/ based on Florfenicol
kg).15,30,45,60,90,135,180,240 and 360min from rat eyeground vein clump takes blood to be placed in painting after administration respectively
Have in the test tube of heparin, 4000rpm is centrifugated to obtain blood plasma.Blood plasma 100 μ l, 300 μ l of acetonitrile on the rocks are taken, be vortexed concussion 30s,
12000rpm is centrifuged 10min, 20 μ l sample introduction of Aspirate supernatant.Florfenicol, chromatographic condition are measured using HPLC- UV detector
It is as follows: chromatographic column: Hypersil ODS2 (250 × 4.6mm, 5 μm), mobile phase: Yi Jing ︰ 0.05mol/L potassium dihydrogen phosphate
(20 ︰ 80, V/V), flow velocity: 1.0ml/min, column temperature: 40 DEG C, sample volume: 20ul, ultraviolet detection wavelength: λ=223nm is sensitive
Degree: 0.005.
2. experimental result
Experimental result as shown in Figure 1, in rat body shown in FIG. 1 Florfenicol Pharmacokinetic experiments the result shows that, the present invention
The florfenicol composition of offer, compared with Florfenicol raw material medicine, florfenicol composition biological utilisation provided by the invention
Degree is significantly improved, and the experimental results showed that, florfenicol composition bioavilability provided by the invention is also obvious
Higher than Florfenicol inclusion compound aqueous solution；Especially 1 part of Florfenicol, 25 parts and 10 parts of CARBOPOL 971 preparations of beta-cyclodextrin
Bioavilability highest after composition is obtained, extraordinary unexpected technical effect is achieved.
The C of Florfenicol inclusion compound provided by the inventionmax, at least 5 times or more are improved than Florfenicol raw material medicine, and
The prior art is compared, if notification number is CN 102885777B, in entitled florfenicol powder composition and preparation method thereof
The florfenicol powder composition maximum blood concentration of state's patent disclosure is 1.7 times of bulk pharmaceutical chemicals, and the present invention improves 5 times or more,
With higher bioavilability, good technical effect is achieved.
The technical concepts and features of embodiment of above only to illustrate the invention, its object is to allow be familiar with technique
People understands the content of present invention and is implemented, and it is not intended to limit the scope of the present invention, and all spirit according to the present invention is real
The equivalent change or modification that matter is done, should be covered by the scope of protection of the present invention.
Claims (1)
1. a kind of suspension of florfenicol composition, it is characterised in that: it is by 1 part of Florfenicol, 25 parts of beta-cyclodextrin, card
Composition is made in the raw material of 10 parts of wave nurse 971P: and then suspension is diluted to 0.5% or 1% carboxymethylcellulose sodium solution
Liquid；
The preparation method of florfenicol composition, comprising the following steps:
(1) 1 part of Florfenicol, 25 parts of beta-cyclodextrin, 10 parts of CARBOPOL 971 are added to the water, are heated to 70~90 DEG C, stirring
30~40 minutes；
(2) solution after above-mentioned stirring is prepared into powder by way of being spray-dried or being lyophilized to get Florfenicol combination
Object；
Or the preparation method of florfenicol composition, comprising the following steps:
(1) 70~90 DEG C in 25 parts of 1 part of Florfenicol, beta-cyclodextrin addition suitable quantity of water, will be heated to, is stirred 30~40 minutes；
(2) solution after above-mentioned stirring is prepared into powder by way of being spray-dried or being lyophilized, then with CARBOPOL 971
10 parts are uniformly mixed to get florfenicol composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510934722.9A CN105477642B (en) | 2015-12-15 | 2015-12-15 | A kind of florfenicol composition of high bioavilability and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510934722.9A CN105477642B (en) | 2015-12-15 | 2015-12-15 | A kind of florfenicol composition of high bioavilability and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105477642A CN105477642A (en) | 2016-04-13 |
| CN105477642B true CN105477642B (en) | 2019-08-06 |
Family
ID=55665145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510934722.9A Active CN105477642B (en) | 2015-12-15 | 2015-12-15 | A kind of florfenicol composition of high bioavilability and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105477642B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105997966A (en) * | 2016-08-03 | 2016-10-12 | 佛山科学技术学院 | Clathrate for controlling aquatic animal bacterial diseases and preparation method thereof |
| CN106390136A (en) * | 2016-08-31 | 2017-02-15 | 河北维尔利动物药业集团有限公司 | Water-soluble florfenicol clathrate with high bioavailability and preparation method of water-soluble florfenicol clathrate |
| CN106420628A (en) * | 2016-09-26 | 2017-02-22 | 保定冀中药业有限公司 | Florfenicol sodium succinate water-soluble granule and preparation method thereof |
| CN108721220A (en) * | 2018-02-14 | 2018-11-02 | 浙江万方生物科技有限公司 | A kind of efficiently water-soluble florfenicol powder and preparation method thereof |
| CN108653213A (en) * | 2018-06-05 | 2018-10-16 | 王琴 | A kind of florfenicol powder and preparation method thereof |
| CN108969486A (en) * | 2018-06-05 | 2018-12-11 | 王琴 | A kind of florfenicol soluble powder and preparation method thereof |
| CN108743541A (en) * | 2018-06-24 | 2018-11-06 | 王琴 | Water-soluble veterinary drug preparation and preparation method thereof |
| CN109053506B (en) * | 2018-08-16 | 2020-05-08 | 天津大学 | Method for preparing florfenicol nano crystal |
| CN112535663A (en) * | 2019-09-23 | 2021-03-23 | 江西邦诚动物药业有限公司 | Instant solid dispersion florfenicol powder and preparation method thereof |
| CN112121016B (en) * | 2020-10-09 | 2022-11-22 | 清远海贝生物技术有限公司 | Water-soluble florfenicol powder and preparation method thereof |
| CN112716902B (en) * | 2021-02-04 | 2021-10-12 | 广州市和生堂动物药业有限公司 | Florfenicol powder and preparation method thereof |
| CN114209656B (en) * | 2021-12-31 | 2023-08-01 | 浙江金朗博药业有限公司 | Florfenicol soluble powder and preparation method thereof |
| CN115894944B (en) * | 2023-01-06 | 2023-05-12 | 四川科宏达集团有限责任公司 | Modified functional surfactant derivative, preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101686956A (en) * | 2007-04-27 | 2010-03-31 | 谢尔英·普劳有限公司 | Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins |
| CN102973489A (en) * | 2012-12-11 | 2013-03-20 | 江西新世纪民星动物保健品有限公司 | Florfenicol solid dispersoid and preparation method thereof |
| CN104825400A (en) * | 2015-05-28 | 2015-08-12 | 中牧南京动物药业有限公司 | Florfenicol included controlled-release preparation and its preparing method and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697730A (en) * | 2012-05-07 | 2012-10-03 | 郑州后羿制药有限公司 | Florfenicol soluble power and preparation method thereof |
-
2015
- 2015-12-15 CN CN201510934722.9A patent/CN105477642B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101686956A (en) * | 2007-04-27 | 2010-03-31 | 谢尔英·普劳有限公司 | Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins |
| CN102973489A (en) * | 2012-12-11 | 2013-03-20 | 江西新世纪民星动物保健品有限公司 | Florfenicol solid dispersoid and preparation method thereof |
| CN104825400A (en) * | 2015-05-28 | 2015-08-12 | 中牧南京动物药业有限公司 | Florfenicol included controlled-release preparation and its preparing method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105477642A (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105477642B (en) | A kind of florfenicol composition of high bioavilability and preparation method thereof | |
| Wang et al. | Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat | |
| CN103211759B (en) | Puerarin nanocrystalline medical composition and preparation method thereof | |
| CN103086346B (en) | A kind of preparation method of mesoporous carbon and application | |
| CN103705469B (en) | A kind of honokiol nanoparticle and preparation method thereof | |
| CN102961750A (en) | Application of silicon dioxide aerogel in pharmacy | |
| CN108186605B (en) | Medicine-carrying nano-particles based on tannic acid and preparation method and application thereof | |
| Wu et al. | Novel preparation of PLGA/HP55 nanoparticles for oral insulin delivery | |
| CN102824356A (en) | Baicalin nano crystal suspension, nano crystal dry powder and methods for preparing baicalin nano crystal suspension and nano crystal dry powder | |
| CN102793706B (en) | The preparation method of Tolvaptan solid dispersion | |
| CN102440996A (en) | Compound albendazole suspension containing ivermectin nanoemulsion and preparation method thereof | |
| CN103655486B (en) | Sirolimus microemulsion particles and its preparation method and application | |
| CN103396521A (en) | Synthesis and micellization application of amphiphilic beta-cyclodextrin star polymer | |
| CN111632032A (en) | Natural small molecule co-assembled nano-drug delivery system and preparation method and application thereof | |
| Kavaz et al. | Low releasing mitomycin C molecule encapsulated with chitosan nanoparticles for intravesical installation | |
| Banerjee et al. | An easy and effective method for radiolabelling of solid lipid nanoparticles | |
| CN101549272A (en) | Method of preparing S/O/W of 5-fluorouracil biodegradable polymer microspheres | |
| CN103655501A (en) | Nano ibuprofen dry powder, tablets and preparation method thereof | |
| CN105534947A (en) | Preparation method of celecoxib nanosuspension capsules | |
| CN108186597A (en) | A kind of Lubiprostone 1 solid dispersions and preparation method thereof | |
| CN103356480B (en) | Oleanolic acid nanometer suspension and preparation method thereof | |
| CN103126991B (en) | Voriconazole nano-micro composite powder and preparation method thereof | |
| CN103301147A (en) | Nanometer compound ceftiofur suspension and preparation method thereof | |
| CN102028655B (en) | Zanamivir solid lipid nanosphere oral preparation and preparation method thereof | |
| Abdulqader et al. | Preparation and characterization of posaconazole as a nano-micelle using d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |